Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.525
-0.005 (-0.33%)
Sep 16, 2025, 4:00 PM EDT - Market closed
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Pliant Therapeutics stock have a consensus rating of "Hold" and an average price target of $3.93, which forecasts a 157.70% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $10.
Price Target: $3.93 (+157.70%)
Analyst Consensus: Hold
* Price targets were last updated on Aug 8, 2025.
Analyst Ratings
The average analyst rating for Pliant Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 2 | 1 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $17 → $4 | Buy | Maintains | $17 → $4 | +162.30% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 4, 2025 |
| Citigroup | Citigroup | Hold Maintains $4 → $1.5 | Hold | Maintains | $4 → $1.5 | -1.64% | Mar 4, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +96.72% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
2.27M
Revenue Next Year
1.70M
from 2.27M
Decreased by -25.01%
EPS This Year
-2.64
from -3.47
EPS Next Year
-1.89
from -2.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 15.8M | |||
| Avg | 2.3M | 1.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 594.8% | |||
| Avg | - | -25.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.37 | -1.08 | |||
| Avg | -2.64 | -1.89 | |||
| Low | -3.07 | -2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.